Cellular reprogramming: A new technology frontier in pharmaceutical research

Amy Brock, Hui Tong Goh, Binxia Yang, Yu Lu, Hu Li, Yuin Han Loh

Research output: Contribution to journalReview article

10 Scopus citations

Abstract

Induced pluripotent stem cells via cellular reprogramming are now finding multiple applications in the pharmaceutical research and drug development pipeline. In the pre-clinical stages, they serve as model systems for basic research on specific diseases and then as key experimental tools for testing and developing therapeutics. Here we examine the current state of cellular reprogramming technology, with a special emphasis on approaches that recapitulate previously intractable human diseases in vitro. We discuss the technical and operational challenges that must be tackled as reprogrammed cells become incorporated into routine pharmaceutical research and drug discovery.

Original languageEnglish (US)
Pages (from-to)35-52
Number of pages18
JournalPharmaceutical research
Volume29
Issue number1
DOIs
StatePublished - Jan 1 2012

Keywords

  • Cellular reprogramming
  • Drug discovery
  • IPSC
  • Pharmaceutical research
  • Stem cells

ASJC Scopus subject areas

  • Biotechnology
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Organic Chemistry
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Cellular reprogramming: A new technology frontier in pharmaceutical research'. Together they form a unique fingerprint.

  • Cite this